Protective conditioning for acute graft-versus-host disease

New England Journal of Medicine

Volumn 353, Issue 13, 2005, Pages 1321-1331

  Lowsky, Robert ^a   Takahashi, Tsuyoshi ^a   Yin, Ping Liu ^a   Dejbakhsh Jones, Sussan ^a   Grumet, F Carl ^a   Shizuru, Judith A ^a   Laport, Ginna G ^a   Stockerl Goldstein, Keith E ^a   Johnston, Laura J ^a   Hoppe, Richard T ^a   Bloch, Daniel A ^a   Blume, Karl G ^a   Negrin, Robert S ^a   Strober, Samuel ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Clinical Sciences Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIINFECTIVE AGENT; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BLOOD DONOR; CANCER RADIOTHERAPY; CANCER REGRESSION; CELL PROLIFERATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DRUG INFUSION; FEMALE; GASTROINTESTINAL INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES ZOSTER; HLA SYSTEM; HUMAN; LYMPH NODE IRRADIATION; LYMPHOCYTOPENIA; LYMPHOMA; MALE; MYCOSIS; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RECIPIENT; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INFECTION;

ACUTE DISEASE; ADULT; AGED; ANTILYMPHOCYTE SERUM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LEUKOPENIA; LYMPHATIC IRRADIATION; LYMPHOMA; MALE; MIDDLE AGED; REMISSION INDUCTION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 25444461935     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa050642     Document Type: Article

References (31)

1. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
2. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-41.
3. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-7.
4. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
5. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-42.
6. Georges GE, Maris M, Sandmaier BM, et al. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol 2002;76:Suppl 1:184-9.
7. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;15:1620-9.
8. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62.
9. Schetelig J, Kroger N, Held TK, et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002;87:299-305.
10. Spitzer TR, MaAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000;6:309-20.
11. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-99.
12. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
13. + T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999;189:1073-81.
14. Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J Immunol 2001;167:2087-96.
15. Lan F, Zeng D, Higuchi M, Higgins JP, Strober S. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 2003;9:355-63.
16. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-5.
17. Seino K, Harada M, Taniguchi M. NKT cells are relatively resistant to apoptosis. Trends Immunol 2004;25:219-21.
18. Kaplan HS, Rosenberg SA. Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials. Cancer Res 1966;26:1268-76.
19. Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R, US Thymoglobulin Multi-Center Study Group. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol 2001;9:29-36.
20. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996;5:213-26.
21. 1997 Revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR Recomm Rep 1997;46(RR-4):1-29.
22. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002;73:1386-91.
23. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-54.
24. Strober S, Benike C, Krishnaswamy S, Engleman EG, Grumet FC. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation 2000;69:1549-54.
25. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
26. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-9.
27. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-8.
28. Karnofsky DA, Abelman WH, Craver LC, Burcherd JH. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948;1:634-56.
29. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994;84:3540-9.
30. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction: regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 1994;152:1004-13.
31. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422-9.